Summary of COVID-19 XAV-19 studies
Hide extended summaries
279 patient XAV-19 early treatment RCT: 1% higher mortality (p=1) and 34% higher progression (p=0.48).
RCT 293 COVID-19 patients showing no significant difference in the primary endpoint (disease aggravation within 8 days) with XAV-19, a glyco-humanized swine polyclonal antibody. While XAV-19 showed no benefit for patients requiring oxygen therapy, it significantly reduced time to improvement for patients not requiring oxygen (7 days vs 14 days, p=0.0159).
Oct 2023, medRxiv, https://www.medrxiv.org/content/10.1101/2023.10.09.23296726, https://c19p.org/poulakou
398 patient XAV-19 late treatment RCT: 90% higher mortality (p=0.29), 106% higher ventilation (p=0.03), 5% higher ICU admission (p=0.9), and 5% higher progression (p=0.82).
RCT 398 hospitalized patients with severe COVID-19 requiring low-flow oxygen therapy showing no significant difference in death or respiratory failure through day 15 with XAV-19 (a swine glyco-humanized polyclonal neutralizing antibody) compared to placebo.
Oct 2023, Open Forum Infectious Diseases, https://academic.oup.com/ofid/article/doi/10.1093/ofid/ofad525/7325964, https://c19p.org/gaborit
279 patient XAV-19 early treatment RCT: 1% higher mortality (p=1) and 34% higher progression (p=0.48).
RCT 293 COVID-19 patients showing no significant difference in the primary endpoint (disease aggravation within 8 days) with XAV-19, a glyco-humanized swine polyclonal antibody. While XAV-19 showed no benefit for patients requiring oxygen therapy, it significantly reduced time to improvement for patients not requiring oxygen (7 days vs 14 days, p=0.0159).
Oct 2023, medRxiv, https://www.medrxiv.org/content/10.1101/2023.10.09.23296726, https://c19p.org/poulakou
398 patient XAV-19 late treatment RCT: 90% higher mortality (p=0.29), 106% higher ventilation (p=0.03), 5% higher ICU admission (p=0.9), and 5% higher progression (p=0.82).
RCT 398 hospitalized patients with severe COVID-19 requiring low-flow oxygen therapy showing no significant difference in death or respiratory failure through day 15 with XAV-19 (a swine glyco-humanized polyclonal neutralizing antibody) compared to placebo.
Oct 2023, Open Forum Infectious Diseases, https://academic.oup.com/ofid/article/doi/10.1093/ofid/ofad525/7325964, https://c19p.org/gaborit
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.